Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchProton Pump InhibitorsPPIs (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study

Blanc et al., Preprints, doi:10.20944/preprints202005.0016.v1
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case 56% Improvement Relative Risk Proton Pump Inhibitors  Blanc et al.  Prophylaxis Do proton pump inhibitors reduce COVID-19 infections? Retrospective 179 patients in France (March - April 2020) Fewer cases with proton pump inhibitors (p=0.0053) c19early.org Blanc et al., Preprints, May 2020 FavorsPPIs Favorscontrol 0 0.5 1 1.5 2+
PPIs for COVID-19
1st treatment shown to increase risk in September 2020, now with p = 0.000000048 from 40 studies.
5,300+ studies for 116 treatments. c19early.org
Retrospective 179 elderly patients in France, showing higher risk of COVID-19 cases with acetaminophen use, without statistical significance.
Study covers proton pump inhibitors and acetaminophen.
risk of case, 56.2% lower, OR 0.44, p = 0.005, treatment 63, control 116, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Blanc et al., 2 May 2020, retrospective, France, preprint, mean age 84.1, 22 authors, study period 2 March, 2020 - 8 April, 2020.
This PaperPPIsAll
DOI record: { "DOI": "10.20944/preprints202005.0016.v1", "URL": "http://dx.doi.org/10.20944/preprints202005.0016.v1", "abstract": "<jats:p>Background: COVID-19 is a disease of the elderly as 95% of deaths related to COVID-19 occur in people over 60 years of age. Despite the urgent need for a preventive treatment there are currently no serious leads, other than the vaccination. Objective: To find a preventive treatment of COVID-19 in elderly patients. Design: Retrospective case-control study. Setting: Robertsau Geriatric Hospital of the University Hospitals of Strasbourg, France. Patients: 179 elderly patients who had been in contact with the SARS-CoV-2, of whom 89 had tested RT-PCR-positive (COVID-pos) for the virus and 90 had tested RT-PCR-negative (COVID-neg). Measurements: Treatments within 15 days prior to RT-PCR (including antihypertensive drugs, antipsychotics, antibiotics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors (PPIs), paracetamol, anticoagulant, oral antidiabetics (OADs), corticosteroids, immunosuppressants), comorbidities, symptoms, laboratory values, and clinical outcome were all collected using the electronic patient record. Results: COVID-pos patients more frequently had a history of diabetes (P=.016) and alcoholism (P=.023), a lower leukocyte count (P=.014) and a higher mortality rate&amp;ndash; 29.2% versus 14.4% &amp;ndash; (P=.014) when compared to COVID-neg patients. Patients on PPIs were 2.3 times less likely (odds ratio [OR] = 0.4381, 95% confidence interval [CI] [0.2331, 0.8175], P=.0053) to develop COVID-19 infection, compared to those not on PPIs. No other treatment decreased or increased this risk. COVID-19 patients on antipsychotics (P=.0013) and OADs (P=.0166) were less likely to die. Limitations: retrospective study. Conclusion: PPIs treatment lowered the risk of development of COVID-19 infection, and antipsychotics and OADs decreased the risk of mortality in geriatric patients. If further studies confirm this finding, PPIs could be used preventatively in the elderly in this pandemic context. Moreover, OADS and antipsychotics should be tested in clinical trials.</jats:p>", "accepted": { "date-parts": [ [ 2020, 4, 28 ] ] }, "author": [ { "affiliation": [], "family": "Blanc", "given": "Frederic", "sequence": "first" }, { "affiliation": [], "family": "Waechter", "given": "Cedric", "sequence": "additional" }, { "affiliation": [], "family": "Vogel", "given": "Thomas", "sequence": "additional" }, { "affiliation": [], "family": "Schorr", "given": "Benoît", "sequence": "additional" }, { "affiliation": [], "family": "Demuynck", "given": "Catherine", "sequence": "additional" }, { "affiliation": [], "family": "Martin-Hunyadi", "given": "Catherine", "sequence": "additional" }, { "affiliation": [], "family": "Meyer", "given": "Maxence", "sequence": "additional" }, { "affiliation": [], "family": "Mutelica", "given": "Denata", "sequence": "additional" }, { "affiliation": [], "family": "Bougaa", "given": "Nadjiba", "sequence": "additional" }, { "affiliation": [], "family": "Fafi-Kremer", "given": "Samira", "sequence": "additional" }, { "affiliation": [], "family": "Calabrese", "given": "Lidia", "sequence": "additional" }, { "affiliation": [], "family": "Schmitt", "given": "Elise", "sequence": "additional" }, { "affiliation": [], "family": "Imperiale", "given": "Delphine", "sequence": "additional" }, { "affiliation": [], "family": "Jehl", "given": "Catherine", "sequence": "additional" }, { "affiliation": [], "family": "Boussuge", "given": "Alexandre", "sequence": "additional" }, { "affiliation": [], "family": "Suna", "given": "Carmen", "sequence": "additional" }, { "affiliation": [], "family": "Weill", "given": "François", "sequence": "additional" }, { "affiliation": [], "family": "Matzinger", "given": "Alexia", "sequence": "additional" }, { "affiliation": [], "family": "Muller", "given": "Candice", "sequence": "additional" }, { "affiliation": [], "family": "Karcher", "given": "Patrick", "sequence": "additional" }, { "affiliation": [], "family": "Kaltenbach", "given": "Georges", "sequence": "additional" }, { "affiliation": [], "family": "Sauleau", "given": "Erik", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 5, 4 ] ], "date-time": "2020-05-04T16:19:38Z", "timestamp": 1588609178000 }, "deposited": { "date-parts": [ [ 2020, 5, 4 ] ], "date-time": "2020-05-04T16:20:08Z", "timestamp": 1588609208000 }, "group-title": "MEDICINE &amp; PHARMACOLOGY", "indexed": { "date-parts": [ [ 2022, 7, 14 ] ], "date-time": "2022-07-14T07:32:23Z", "timestamp": 1657783943788 }, "is-referenced-by-count": 5, "issued": { "date-parts": [ [ 2020, 5, 2 ] ] }, "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 5, 2 ] ], "date-time": "2020-05-02T00:00:00Z", "timestamp": 1588377600000 } } ], "member": "1968", "original-title": [], "posted": { "date-parts": [ [ 2020, 5, 2 ] ] }, "prefix": "10.20944", "published": { "date-parts": [ [ 2020, 5, 2 ] ] }, "publisher": "MDPI AG", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://www.preprints.org/manuscript/202005.0016/v1" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study", "type": "posted-content" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit